Extended courses of oral nirmatrelvir and ritonavir combination therapy (Paxlovid; Pfizer) may have meaningful clinical benefits for some patients with post-COVID syndrome, also known as long COVID; however, not everyone with the condition benefits from extended therapy.1,2
Paxlovid may provide benefits to some patients with long COVID. | Image Credit: © J.A. | stock.adobe.com
Patients with long COVID, a chronic condition associated with SARS-CoV-2 infection—the virus that causes COVID-19—experience symptoms that persist for more than 12 weeks following an acute infection. The illness can last weeks, months, or years following a bout with COVID-19; anyone who has had a COVID-19 infection can experience long COVID, and data suggest that approximately 7% of US adults have reported having long COVID.1,3
The combination of…